<DOC>
	<DOCNO>NCT00409760</DOCNO>
	<brief_summary>This trial compare valsartan amlodipine combination therapy valsartan amlodipine , placebo treatment hypertension .</brief_summary>
	<brief_title>Safety Efficacy Valsartan Amlodipine Combined Alone Patients With Hypertension .</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Amlodipine , Valsartan Drug Combination</mesh_term>
	<criteria>Outpatients 18 year old . Male female patient eligible . Female patient must either postmenopausal one year surgically sterile , use effective contraceptive method barrier method spermicide intrauterine device . Hormonal contraceptive use disallow . Patients mild moderate essential diastolic hypertension ( grade 1 2 WHO classification ) measure calibrated standard sphygmomanometer . Patients must MSDBP &gt; = 90 mmHg &lt; 110 mmHg Visit 1 ( week 2 4 ) , MSDBP &gt; = 95 mmHg &lt; 110 mmHg Visit 2 ( week 0 ) . Patients must absolute difference = &lt; 10 mmHg average sit diastolic blood pressure Visits 1 2 . Patients eligible able participate study , consent purpose nature investigation clearly explain ( write inform consent ) . Severe hypertension ( grade 3 WHO classification ; MSDBP &gt; =110 mmHg diastolic and/or MSSBP &gt; = 180 mmHg systolic ) . Inability discontinue prior antihypertensive medication safely period 14 week ) . Known KeithWagener grade III IV hypertensive retinopathy . History hypertensive encephalopathy cerebrovascular accident anytime prior Visit 1 ( week 2 4 ) . Transient ischemic cerebral attack last 12 month prior Visit 1 ( week 2 4 ) . Evidence secondary form hypertension , coarctation aorta , hyperaldosteronism , unilateral renal artery stenosis , pheochromocytoma , etc . Type 1 Diabetes Mellitus . Type 2 Diabetes Mellitus poor glucose control define fast glycosylated hemoglobin ( HbA1c ) &gt; 8 % Visit 1 ( week 2 4 ) . Administration agent indicate treatment hypertension within minimum 4 week prior randomization study ( Visit 2 , week 0 ) , permit exception antihypertensive medication require taper commence Visit 0 ( week 4 6 ) . Known suspected contraindication , include history allergy angiotensin receptor blocker calcium channel blocker . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>HYEPRTENSION , VALSARTAN , AMLODIPINE , high blood pressure</keyword>
</DOC>